Adam S Adler
Overview
Explore the profile of Adam S Adler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
2367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
High-throughput specificity profiling of antibody libraries using ribosome display and microfluidics
Wagner E, Carter K, Lim Y, Chau G, Enstrom A, Wayham N, et al.
Cell Rep Methods
. 2024 Dec;
4(12):100934.
PMID: 39689695
In this work, we developed PolyMap (polyclonal mapping), a high-throughput method for mapping protein-protein interactions. We demonstrated the mapping of thousands of antigen-antibody interactions between diverse antibody libraries isolated from...
2.
Wayham N, Niedecken A, Simons J, Chiang Y, Medina-Cucurella A, Mizrahi R, et al.
J Infect Dis
. 2023 Apr;
228(5):555-563.
PMID: 37062677
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) possess mutations that prevent antibody therapeutics from maintaining antiviral binding and neutralizing efficacy. Monoclonal antibodies (mAbs) shown to neutralize Wuhan-Hu-1...
3.
Lim Y, Ramirez N, Asensio M, Chiang Y, Muller G, Mrovecova P, et al.
J Clin Immunol
. 2023 Feb;
43(5):940-950.
PMID: 36826743
Purpose: Most individuals with antibody deficiency (hypogammaglobulinemia) need immunoglobulin replacement therapy (IgG-RT) from healthy plasma donors to stay clear of infections. However, a small subset of hypogammaglobulinemic patients do not...
4.
Mizrahi R, Lin W, Gras A, Niedecken A, Wagner E, Keating S, et al.
Pathogens
. 2022 Jul;
11(7).
PMID: 35890050
Conventionally, hyperimmune globulin drugs manufactured from pooled immunoglobulins from vaccinated or convalescent donors have been used in treating infections where no treatment is available. This is especially important where multi-epitope...
5.
Lim Y, Adler A, Johnson D
MAbs
. 2022 Apr;
14(1):2069075.
PMID: 35482911
The antibody drug field has continually sought improvements to methods for candidate discovery and engineering. Historically, most such methods have been laboratory-based, but informatics methods have recently started to make...
6.
Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
Lim Y, Coles G, Sandhu S, Johnson D, Adler A, Stone E
BMC Biol
. 2021 May;
19(1):107.
PMID: 34030676
Background: The anti-tumor activity of anti-PD-1/PD-L1 therapies correlates with T cell infiltration in tumors. Thus, a major goal in oncology is to find strategies that enhance T cell infiltration and...
7.
Keating S, Mizrahi R, Adams M, Asensio M, Benzie E, Carter K, et al.
Nat Biotechnol
. 2021 Apr;
39(8):989-999.
PMID: 33859400
Plasma-derived polyclonal antibody therapeutics, such as intravenous immunoglobulin, have multiple drawbacks, including low potency, impurities, insufficient supply and batch-to-batch variation. Here we describe a microfluidics and molecular genomics strategy for...
8.
Simons J, Lim Y, Carter K, Wagner E, Wayham N, Adler A, et al.
MAbs
. 2020 Aug;
12(1):1803646.
PMID: 32744131
affinity maturation of therapeutic monoclonal antibodies is commonly applied to achieve desired properties, such as improved binding kinetics and affinity. Currently there are no universally accepted protocols for generation of...
9.
Spindler M, Nelson A, Wagner E, Oppermans N, Bridgeman J, Heather J, et al.
Nat Biotechnol
. 2020 May;
38(5):609-619.
PMID: 32393905
T cells engineered to express antigen-specific T cell receptors (TCRs) are potent therapies for viral infections and cancer. However, efficient identification of clinical candidate TCRs is complicated by the size...
10.
Medina-Cucurella A, Mizrahi R, Asensio M, Edgar R, Leong J, Leong R, et al.
Antibodies (Basel)
. 2019 Sep;
8(1).
PMID: 31544823
To discover therapeutically relevant antibody candidates, many groups use mouse immunization followed by hybridoma generation or B cell screening. One modern approach is to screen B cells by generating natively...